B+
Bull case
25%
Probability
Target price
$3.35
+13.6% vs current
GDRX
GoodRxANasdaq / Health Care Equipment & Services
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
45%
Probability
Target price
$2.80
-5.1% vs current
B-
Bear case
30%
Probability
Target price
$2.10
-28.8% vs current
AI sentiment snapshot
Latest data as of 2026-05-09
Recent news sentiment (30D)
-26.5
Negative
Company
-
Unavailable
Macro
-26.5
Negative
Pulse
-
Unavailable
Sentiment proxy
+41.1
Score
AI commentary
This T+3 follow-up modestly improves the setup versus the prior baseline because the company did confirm a better-than-feared quarter and raised full-year expectations on May 6, 2026. Immediate market tone appeared constructive in secondary coverage, and the 2026-05-07 anchor close of $2.84 suggests no post-print collapse. Still, delayed analyst revision evidence is thin, coverage remains low, and the key debate has not changed: newer Pharma Direct and subscription growth is improving, but the legacy prescription transaction base is still deteriorating. That keeps this as a cautious monitoring name rather than a high-conviction bullish turn.
RankAlpha Sentiment Codex - 2026-05-09
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-31catalystQ1 results cleared a low bar and management raised FY2026 expectationsHigh impact
GoodRx reported Q1 2026 revenue of $194.0 million, with Pharma Direct revenue up 82% and subscription revenue up 16%, and raised full-year revenue guidance to $765-$785 million with adjusted EBITDA above $235 million; that helps the near-term narrative, although total revenue still fell 4% year over year [#8-K-2026-05-06].
2026-08-31eventNext print must show new-growth mix can keep offsetting legacy prescription pressureHigh impact
The earnings release still showed prescription transactions revenue down 24% year over year and management said lower unit economics should continue in the near term, so the next quarterly update needs to prove Pharma Direct and subscriptions can more durably offset weakness in the core transaction base [#8-K-2026-05-06] [#10-Q-2026-05-06].
2026-12-31catalystManufacturer and self-pay drug access expansion can deepen the platform, but materiality is still earlyHigh impact
Recent product-access announcements around Lilly oral GLP-1 availability, Wegovy HD, and additional diabetes/weight-management offerings support the thesis that GoodRx is becoming a broader manufacturer and self-pay access channel, but current evidence still points to an early mix shift rather than a proven multi-year growth reacceleration.
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-09 • Updated nightlySource: Internal modelMethodology